Hematology is in our blood

Boule Diagnostics AB is a company with a strong heritage when it comes to hematology diagnostics. We developed the very first European blood cell counter, and today our instruments, reagents, calibrators and controls are used by healthcare providers around the world. Boule’s products are currently on sale in more than 100 countries.

Our blood tests help provide one of the first and most important indicators of a disease state and Boule systems play an increasingly important role in helping build the infrastructure of healthcare for small and medium size patient care environments in both human and veterinary markets.

Boule is listed on NASDAQ Stockholm since June 2011.

Interview with Boules CEO Fredrik Dalborg answering questions about Q1.

Financial Calendar

Interim report Q3
2018-11-06

Year-end report
2019-02-07

Annual report 2018
2019-04-15

Interim report Q1
2019-05-06

Annual General Meeting 2019
2019-05-06

Event

Welcome to visit us at Medica

12-15 november, Düsseldorf, Gremnay

 Booth no. 3A47

 

Company in figures 2017

0

Net sales, SEK million
(increased by 8%)

0

Operating profit, SEK million
(increased by 15%)

0 %

Gross margin
(decreased by 1%)

0 %

Equity/assets ratio
(same as 2016)